Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1585-1593

  Lin, Liang ^a   Zhao, Ying Jiao ^a   Chew, Paul T K ^b   Sng, Chelvin C A ^b   Wong, Hon Tym ^c   Yip, Leonard W ^c   Wu, Tuck Seng ^b   Bautista, Dianne ^d   Teng, Monica ^a   Khoo, Ai Leng ^a   Lim, Boon Peng ^a  

^a NATIONAL HEALTHCARE GROUP   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d SINGAPORE CLINICAL RESEARCH INSTITUTE   (Singapore)

Author keywords

bimatoprost; glaucoma; intraocular pressure; latanoprost; meta analysis; network meta analysisIntroduction; ocular hypertension; systematic review; tafluprost; travoprost

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TAFLUPROST; TIMOLOL; TRAVOPROST; AMIDE; ANTIHYPERTENSIVE AGENT; CLOPROSTENOL; PROSTAGLANDIN F;

BLURRED VISION; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EYE IRRITATION; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; OPEN ANGLE GLAUCOMA; PAIN; PRIORITY JOURNAL; PRURITUS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; OCULAR HYPERTENSION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AMIDES; ANTIHYPERTENSIVE AGENTS; BIMATOPROST; CLOPROSTENOL; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIMOLOL; TRAVOPROST;

EID: 84921521015     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014548569     Document Type: Review

References (53)

1. Kingman S.Glaucoma is second leading cause of blindness globally.Bull World Health Organ. 2004;82:887-888
2. Quigley HA,Broman AT.The number of people with glaucoma worldwide in 2010 and 2020.Br J Ophthalmol. 2006;90:262-267
3. Varma R,Lee PP,Goldberg I,Kotak S.An assessment of the health and economic burdens of glaucoma.Am J Ophthalmol. 2011;152:515-522
4. Heijl A,Leske MC,Bengtsson B,Hyman L,Bengtsson B,Hussein M.Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.Arch Ophthalmol. 2002;120:1268-1279
5. Lee AJ,McCluskey P.Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.Clin Ophthalmol. 2010;4:741-764
6. Camras CB.Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.Ophthalmology. 1996;103:138-147
7. Fellman RL,Sullivan EK,Ratliff M, et al.Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.Ophthalmology. 2002;109:998-1008
8. Whitcup SM,Cantor LB,VanDenburgh AM,Chen K.A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension.Br J Ophthalmol. 2003;87:57-62
9. Chabi A,Varma R,Tsai JC, et al.Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol. 2012;153:1187-1196
10. Orzalesi N,Rossetti L,Bottoli A,Fogagnolo P.Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.Ophthalmology. 2006;113:239-246
11. Alagoz G,Gurel K,Bayer A, et al.A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients.Ophthalmologica. 2008;222:88-95
12. Chander A,Kapoor H,Thomas S.Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma.Nepal J Ophthalmol. 2013;5:75-80
13. Schnober D,Hofmann G,Maier H,Scherzer ML,Ogundele AB,Jasek MC.Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension.Clin Ophthalmol. 2010;4:1459-1463
14. Holmstrom S,Buchholz P,Walt J,Wickstrom J,Aagren M.Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.Curr Med Res Opin. 2005;21:1875-1883
15. Aptel F,Cucherat M,Denis P.Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.J Glaucoma. 2008;17:667-673
16. Cheng JW,Wei RL.Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure.Clin Ther. 2008;30:622-632
17. Denis P,Lafuma A,Khoshnood B,Mimaud V,Berdeaux G.A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.Curr Med Res Opin. 2007;23:601-608
18. Eyawo O,Nachega J,Lefebvre P, et al.Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis.Clin Ophthalmol. 2009;3:447-456
19. Li N,Chen XM,Zhou Y,Wei ML,Yao X.Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.Clin Experiment Ophthalmol. 2006;34:755-764
20. Orme M,Collins S,Dakin H,Kelly S,Loftus J.Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.Curr Med Res Opin. 2010;26:511-528
21. Caldwell DM,Ades AE,Higgins JPT.Simultaneous comparison of multiple treatments: combining direct and indirect evidence.BMJ. 2005;331 (7521): 897-900
22. Jansen JP,Fleurence R,Devine B, et al.Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.Value Health. 2011;14:417-428
23. European Glaucoma Society. Terminology and guidelines for glaucoma. http://www.eugs.org/eng/EGS_guidelines.asp. Accessed March 1, 2014.
24. Mavridis D,Salanti G.A practical introduction to multivariate meta-analysis.Stat Methods Med Res. 2013;22:133-158
25. White IR.Multivariate random-effects meta-regression: updates to mvmeta.Stata J. 2011;11:255-270
26. Higgins JPT,Jackson D,Barrett JK,Lu G,Ades AE,White IR.Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.Res Synthesis Methods. 2012;3:98-110
27. DuBiner H,Cooke D,Dirks M,Stewart WC,VanDenburgh AM,Felix C.Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.Surv Ophthalmol. 2001;45:S353-S360
28. Gandolfi S,Simmons ST,Sturm R,Chen K,VanDenburgh AM.Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.Adv Ther. 2001;18:110-121
29. Konstas AG,Katsimbris JM,Lallos N,Boukaras GP,Jenkins JN,Stewart WC.Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.Ophthalmology. 2005;112:262-266
30. Noecker RS,Dirks MS,Choplin NT,Bernstein P,Batoosingh AL,Whitcup SM.A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.Am J Ophthalmol. 2003;135:55-63
31. Parrish RK,Palmberg P,Sheu WP.A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.Am J Ophthalmol. 2003;135:688-703
32. Walters TR,DuBiner HB,Carpenter SP,Khan B,VanDenburgh AM.24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.Surv Ophthalmol. 2004;49:S26-S35
33. Traverso CE,Ropo A,Papadia M,Uusitalo H.A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.J Ocul Pharmacol Ther. 2010;26:97-104
34. Uusitalo H,Pillunat LE,Ropo A.Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.Acta Ophthalmol. 2010;88:12-19
35. Cardascia N,Vetrugno M,Trabucco T,Cantatore F,Sborgia C.Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma.Curr Ther Res. 2003;64:389-400
36. Maul E,Carrasco FG,Costa VP, et al.A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.Clin Ther. 2007;29:1915-1923
37. Cantor LB,Hoop J,Morgan L,Wudunn D,Catoira Y.Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.Br J Ophthalmol. 2006;90:1370-1373
38. Macky TA.Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.J Ocul Pharmacol Ther. 2010;26:605-610
39. Noecker RJ,Earl ML,Mundorf TK,Silverstein SM,Phillips MP.Comparing bimatoprost and travoprost in black Americans.Curr Med Res Opin. 2006;22:2175-2180
40. Brandt JD,VanDenburgh AM,Chen K,Whitcup SM.Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial.Ophthalmology. 2001;108:1023-1031
41. Martin E,Martinez-de-la-Casa JM,Garcia-Feijoo J,Troyano J,Larrosa JM,Garcia-Sanchez J.A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients.Eye (Lond). 2007;21:164-168
42. Alm A.Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure.Adv Prostaglandin Thromboxane Leukot Res. 1995;23:527-532
43. Kitnarong N,Zhao Y,Netland PA,Kent AR.Efficacy of latanoprost and timolol maleate in black and white patients.Adv Ther. 2004;21:203-213
44. Mishima HK,Masuda K,Kitazawa Y,Azuma I,Araie M.A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week study.Arch Ophthalmol. 1996;114:929-932
45. Netland PA,Landry T,Sullivan EK, et al.Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol. 2001;132:472-484
46. Quaranta L,Gandolfo F,Turano R, et al.Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.Invest Ophthalmol Vis Sci. 2006;47:2917-2923
47. Sihota R,Saxena R,Agarwal HC,Pandey RM,Gulati V.Peak pressures: crossover study of timolol and latanoprost.Eur J Ophthalmol. 2003;13:546-552
48. Watson P,Stjernschantz J.A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.Ophthalmology. 1996;103:126-137
49. Aquino MV,Lat-Luna M.The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension.Asian J Ophthalmol. 1999;1:3-7
50. Goldberg I,Cunha-Vaz J,Jakobsen JE,Nordmann JP,Trost E,Sullivan EK.Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.J Glaucoma. 2001;10:414-422
51. Katz LJ,Cohen JS,Batoosingh AL,Felix C,Shu V,Schiffman RM.Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension.Am J Ophthalmol. 2010;149:661-671
52. Gandolfi S,Paredes T,Goldberg I, et al.Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.Eur J Ophthalmol. 2012;22:34-44
53. Primary open-angle glaucoma suspect.San Francisco (CA): American Academy of Ophthalmology. 2010;: